---
document_datetime: 2023-09-21 21:46:49
document_pages: 20
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/erivedge-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: erivedge-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 31.1251442
conversion_datetime: 2025-12-18 21:18:00.400306
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## Erivedge

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                       | Opinion/ Notification 1 issued on   | Commission Decision Issued² / amended on   | Product Information affected3   | Summary                        |
|----------------------|---------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|---------------------------------|--------------------------------|
| N/0053               | Minor change in labelling or package leaflet not connectedwith theSPC(Art.61.3Notification) | 15/03/2023                          |                                            | PL                              |                                |
| PSUSA/10140 /202101  | PeriodicSafetyUpdateEUSingle assessment- vismodegib                                         | 02/09/2021                          | n/a                                        |                                 | PRACRecommendation-maintenance |

1 Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions areissuedforallotherprocedures.

3 SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

2A Commission decision(CD) is issued for procedures that affect the terms of the marketing authorisation(e.g.summary of product characteristics,annex II, labelling,package leaflet).The CD is issued within twomonths of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation(EU) No.712/2012, or within one yearfor other procedures.

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| R/0050              | Renewal of themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 22/04/2021   | 01/07/2021   | Annex II, Labelling and PL   |                                |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------|--------------------------------|
| IA/0051/G           | This was an applicationfor a group of variations. B.II.b.2.a-Change to importer,batch release arrangements andqualitycontrol testingof theFp- Replacement/addition of a site where batch control/testingtakesplace B.II.b.2.a-Change to importer,batch release arrangements andqualitycontrol testingof theFp- Replacement/additionofasitewherebatch                                                                                                                                                                                                         | 22/03/2021   | n/a          |                              |                                |
| PSUSA/10140 /202001 | PeriodicSafetyUpdateEUSingleassessment- vismodegib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 03/09/2020   | n/a          |                              | PRACRecommendation-maintenance |
| I1/0046             | Update of the Educational Materials provided as part of the Erivedge Pregnancy Prevention Program, following conclusion of PSUSA/00010140/201901. AnnexIIDisupdatedaccordingly.Additionally,RMP v14.0 is submitted.Furthermore,section 4.4of the SmPC is updated to remove the warning on cutaneoussquamouscell carcinoma.TheMAHalso tooktheopportunitytoupdatethePackageLeaflet withtherecommendedwordingonsodiumcontent. C.1.11.z-Introduction of,or change(s) to, the obligations andconditionsof amarketing authorisation,includingtheRMP-Othervariation | 03/09/2020   | 01/07/2021   | SmPC, Annex II and PL        |                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IA/0049/G   | This was an application for a group of variations.                                                                      | 29/06/2020   | n/a   |
|-------------|-------------------------------------------------------------------------------------------------------------------------|--------------|-------|
| IA/0048     | B.II.e.7.a -Change in supplier of packaging components or devices (when mentioned in the dossier)-Deletionof a supplier | 20/05/2020   | n/a   |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| IB/0045/G   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 13/03/2020   | n/a   |
|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|
|             | This was an application for a group of variations. A.7-Administrativechange-Deletionof manufacturingsites B.I.a.1.f-Change in the manufacturer of AS orof a startingmaterial/reagent/intermediateforAS- Changes to quality control testing arrangements for theAS-replacementoradditionofasitewhere batch control/testing takesplace B.I.a.1.f-Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS- Changestoqualitycontroltestingarrangementsfor theAS-replacementoradditionofasitewhere batchcontrol/testingtakesplace B.I.a.1.f-Change in themanufacturer ofASor of a startingmaterial/reagent/intermediateforAS- Changestoquality control testing arrangementsfor theAS-replacementoradditionofasitewhere batch control/testing takes place B.I.a.1.z - Change in the manufacturer of AS or of a startingmaterial/reagent/intermediateforAS-Other variation B.I.a.2.a-Changes in the manufacturingprocess of theAS-Minor changein themanufacturingprocess of theAS B.I.a.3.b-Change inbatch size(including batch size ranges)ofASorintermediate-Downscaling down to |              |       |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| and/or limits of anAS,starting material/intermediate/reagent-Deletion of a non- significantspecificationparameter(e.g.deletion of an obsoleteparameter) B.I.b.1.d-Change in the specification parameters and/orlimits ofanAS,starting material/intermediate/reagent-Deletionofanon- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure B.I.b.2.c-Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changesto a testprocedurefor a reagent,which doesnothavea significanteffecton theoverall quality of the AS B.1.b.2.c-Change in test procedure forAS or startingmaterial/reagent/intermediate-Other changestoa testprocedurefor areagent,which doesnothaveasignificanteffectontheoverall quality of theAS   |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|                     | startingmaterial/reagent/intermediate-Other changesto a testprocedurefor a reagent,which doesnothave asignificanteffecton theoverall quality of the AS B.I.b.2.e - Change in test procedure for AS or startingmaterial/reagent/intermediate-Other changestoa testprocedure(includingreplacement or addition) for the AS or a starting material/intermediate B.I.c.z-Container closure system of the AS-Other variation B.I.d.1.c-Stability of AS-Change in the re-test period/storageperiodorstorageconditions-Change to an approved stability protocol   |            |            |             |                                                                                                                                      |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10140 /201901 | PeriodicSafetyUpdateEUSingle assessment- vismodegib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 19/09/2019 | 11/11/2019 | SmPC and PL | Refer to Scientific conclusions and grounds recommending thevariationto termsof theMarketingAuthorisation(s)'for PSUSA/10140/201901. |
| IA/0043/G           | This was an application for a group of variations. A.5.b-Administrative change-Change in thename and/oraddressofamanufacturer/importerofthe finishedproduct,including qualitycontrol sites (excludingmanufacturerforbatchrelease) A.7-Administrative change-Deletion of manufacturing sites                                                                                                                                                                                                                                                               | 13/03/2019 | n/a        |             |                                                                                                                                      |
| IAIN/0042           | C.I.12-Inclusion or deletion of blacksymbol and explanatorystatementsformedicinalproductsinthe list of medicinalproducts that aresubject to additional monitoring                                                                                                                                                                                                                                                                                                                                                                                         | 18/12/2018 | 11/11/2019 | SmPC and PL |                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PSUSA/10140 /201801   | PeriodicSafetyUpdateEUSingleassessment- vismodegib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 20/09/2018   | 22/11/2018   |             | RefertoScientificconclusionsandgroundsrecommending thevariationtotermsof theMarketingAuthorisation(s)'for                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
|-----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0041               | B.II.b.2.a - Change to importer, batch release arrangements andquality controltesting of theFP- Replacement/addition of a site wherebatch control/testingtakesplace                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 09/08/2018   | n/a          |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| I1/0039/G             | This was an application for a group of variations. C.I.4UpdateofSmPCsection4.4inordertoupdate thespecialwarningsandprecautionsforuse on the effectsofpost-nataldevelopmentand4.8inorderto include a new adverse event (precocious puberty) observed in children in post marketing. C.I.11.z To submit the final study report for observationalstudyML28296(postapproval commitmentMEA18)andreflectthenewlyavailable informationintheRMPwhichisupdated toversion 13.0. Inaddition,theMarketingauthorisationholder (MAH)tooktheopportunity toincludesomeeditorial changesintheproductinformationandupdatethe local representativeforMalta. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance data C.I.11.z-Introduction of, or change(s) to, the obligations and conditions of a marketing | 12/07/2018   | 22/11/2018   | SmPC and PL | Followingtwo caseevents ofprecociouspubertylisted in theRocheSafetyDatabasefromtheInvestigator- SponsoredTrialML28353inpaediatricpatientswith medulloblastoma,theMAHpreparedanassessmentof precociouspubertyinpaediatricpatientsafter the administrationofErivedge.Baseduponthestrengthof evidenceinthetwocases,whichissupportedbyapositive temporalassociation and aplausiblemechanism,it is consideredthatprecociouspubertyiscausallyassociated withvismodegibadministrationinpaediatricpatients and reported as new adverse drug reaction in section 4.8 of the SmPCwith a frequency\"notknown\".Due to the long drug eliminationhalf-life,this may occur orprogress after drug discontinuation.Section4.4oftheSmPContheeffectson post-natal development isupdated accordingly. |

<div style=\"page-break-after: always\"></div>

|           | authorisation,includingtheRMP-Othervariation                                                                                                                                                                                                                                                                                                                                                                 |            |            |                        |                     |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|---------------------|
| IG/0949/G | This was an applicationfor a group of variations. B.IIl.1.b.2-Submissionofanew/updatedor deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/orexcipientfroma newor an already approvedmanufacturer B.Ill.1.b.4-Submissionofanew/updatedor deletion ofPh.Eur.TSE Certificate ofSuitability- Deletionofcertificates(incasemultiplecertificates | 04/06/2018 | n/a        |                        | exist per material) |
| T/0037    | TransferofMarketingAuthorisation                                                                                                                                                                                                                                                                                                                                                                             | 20/02/2018 | 15/03/2018 | SmPC, Labelling and PL |                     |
|           | This was an applicationfor a group of variations. B.I.a.2.a-Changesinthemanufacturingprocessof theAS-Minor change in themanufacturingprocess of the AS B.I.b.2.a-Change in test procedure for AS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure                                                                                                                             | 20/12/2017 | n/a        |                        | IA/0036/G           |
|           | This was an application for a group of variations. B.I.b.2.a-Change in test procedure forAS or startingmaterial/reagent/intermediate-Minor changestoanapprovedtestprocedure                                                                                                                                                                                                                                  | 04/12/2017 | n/a        |                        | IB/0035/G           |

<div style=\"page-break-after: always\"></div>

|                     | B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation B.I.b.1.z-Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent-Othervariation   |            |            |             |                                |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------|
| PSUSA/10140 /201701 | PeriodicSafetyUpdateEUSingle assessment- vismodegib                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 01/09/2017 | n/a        |             | PRACRecommendation-maintenance |
| IB/0034             | C.1.11.z-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/06/2017 | n/a        |             |                                |
| 11/0032             | C.I.4 -Change(s) in the SPC,Labelling or PL due to new quality,preclinical, clinical orpharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 21/04/2017 | 09/10/2017 | SmPC and PL |                                |
| IB/0031/G           | This was an application for a group of variations. B.I.d.1.a.4-StabilityofAS-Changeinthere-test period/storage period-Extension or introduction of a                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | 30/11/2016 | n/a        |             |                                |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | re-testperiod/storageperiodsupportedbyreal time data B.I.d.1.z-Stability of AS -Change in the re-test period/storageperiodorstorageconditions-Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |                       |                                                                          |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|--------------------------------------------------------------------------|
| II/0025/G | This was an applicationfor a group of variations. Update of sections 4.4,4.6,4.8 and5.1 of theSmPC in order toupdatesafety and efficacyinformation in theproduct information afterfinalisation ofstudy MO25616(S0B013).Consideringthefulfilmentof thespecificobligationsamarketingauthorisationnot subject tospecificobligationsisrecommendedtobe grantedinsteadof theconditional MA.Datafrom the samestudyalsofulfilledtheanalysisrequiredinMEA 005regarding evaluation of the timefor washout of vismodegibaftertreatmentdiscontinuationandin MEAoo8regardingreportingofadverseevents.The PackageLeaflet and theRMP(Version10.1)are updated accordingly. Furthermore theMarketing authorisationholder (MAH)has taken the opportunity toupdate theRMP (version10.1)based on theresultsfrom nonclinical studiesassessedwithinvariation EMEA/H/C/002602/I/21andtoproposedeletionof hyponatraemiaasanimportantpotential riskinthe RMP(version 10.1)and as anADR in the EU Product Information as discussed inpreviousPSUR (EMEA/H/C/PSUSA/00010140/201407). | 15/09/2016 | 14/11/2016 | SmPC, Annex II and PL | Please refer to the published assessmentreport Erivedge- 2602-II-0015/G. |

<div style=\"page-break-after: always\"></div>

|                     | C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality,preclinical, clinical or pharmacovigilance data C.I.11.z-Introduction of,or change(s)to,the obligations and conditions of a marketing authorisation,including theRMP-Othervariation C.1.11.z-Introduction of,or change(s) to, the obligations and conditions of a marketing authorisation,including the RMP-Other variation     |            |            |                   |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0030             | B.II.f.1.b.1 -Stability of FP-Extension of the shelf lifeofthefinishedproduct-Aspackagedforsale (supported by real time data)                                                                                                                                                                                                                                                                  | 11/11/2016 | 09/10/2017 | SmPC              |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| PSUSA/10140 /201601 | PeriodicSafetyUpdateEUSingleassessment- vismodegib                                                                                                                                                                                                                                                                                                                                             | 15/09/2016 | 11/11/2016 | SmPC and Annex II | PleaserefertoErivedge EMEA/H/C/PSUSA/00010140/201601EPAR:Scientific conclusionsandgroundsrecommendingthevariationtothe termsof themarketing authorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| I1/0029             | Update ofsections4.2,4.4 and4.8of theSmPCwith additional informationtodescribetheriskof epiphysesprematurefusion inpaediatricpatients. ThePLandRMP(newversionv.11.0)havebeen updated accordingly. TheMAH has also taken the opportunity toinclude aneditorialchangeinsection5.2. C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical,clinical orpharmacovigilance data | 15/09/2016 | 11/11/2016 | SmPC and PL       | Threecasesofprematurefusioninchildren2-8yearshave beenidentifiedinthereporteddata.Atemporalpattern wassuggestive ofacausalrelationship,andamore probablealternativeexplanationwaslacking.Precocious puberty,a possible consequence of CNS tumors and radiation,wasonlydescribedinonepatient.Basedonthis datasection4.4oftheSmPCisupdatedtowarnthat premature fusion of the epiphyses has been reported in patientsexposed toErivedge.Duetothelongdrug eliminationhalf-life,fusionmay occurorprogressafter drug discontinuation.Section4.8is updatedtoadd Epiphysesprematurefusionasanewadverseeventwitha frequency category of unknown as it cannot be estimated |

<div style=\"page-break-after: always\"></div>

|           |                                                                                                                                                                                                                                                                                                        |            |            |                        | from the availabledata.Section4.2is updatedtoremove that\"no data are available”under the paediatric population sub-heading.The RMP is updated to upgrade theimportant riskonpostnataldevelopmentfrompotentialtoidentified since the risk of epiphyses premature fusion initially observedinanimalshasnowbeenobservedinpatients.                                                                                                            |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0028   | B.II.f.1.d - Stability of FP - Change in storage conditionsofthefinishedproductorthe diluted/reconstituted product                                                                                                                                                                                     | 14/06/2016 | 11/11/2016 | SmPC, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| R/0023    | Renewalof themarketing authorisation.                                                                                                                                                                                                                                                                  | 01/04/2016 | 26/05/2016 |                        | The CHMP,having reviewed the availableinformation on thestatusof thefulfilmentofSpecificObligations and havingconfirmedthepositivebenefitriskbalance,isof the opinion thatthe quality,safety andefficacy of this medicinalproductcontinuetobeadequatelyand sufficientlydemonstratedandthereforerecommendsthe renewalof theconditional MAforErivedge,subjectto the SpecificObligations and Conditions aslaid down inAnnexII to the Opinion. |
| IA/0026/G | This was an applicationfor a group of variations. B.I.a.2.a-Changes in the manufacturing process of theAS-Minor changein themanufacturingprocess of theAS B.I.a.3.a -Change inbatch size(including batch size ranges)ofASorintermediate-Upto10-fold increasecomparedtotheoriginally approvedbatch size | 26/04/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                            |
| IG/0667/G | This was an application for a group of variations.                                                                                                                                                                                                                                                     | 08/04/2016 | n/a        |                        |                                                                                                                                                                                                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|         | B.II1.1.b.2-Submissionofanew/updatedor deletion ofPh.Eur.TSE Certificate of Suitability- New certificate for a starting material/reagent/intermediate/orexcipientfroma neworanalreadyapprovedmanufacturer B.II1.1.b.3-Submission of a new/updated or deletion of Ph.Eur.TSE Certificate of Suitability- Updatedcertificatefrom analready approved manufacturer B.III.1.b.4-Submission of a new/updated or deletion ofPh.Eur.TSE Certificate of Suitability - Deletionofcertificates(incasemultiplecertificates exist per material)   |            |            |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0021 | Updateofsections4.6and5.3oftheSmPCinorder toupdatetheinformationonvismodegibeffectson fertility(MEA002).ThePackageLeafletis updated accordingly.Inaddition,theMarketing authorisation holder(MAH)tookthe opportunity tobring thePIin linewith thelatestQRDtemplateversion10.0. C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data                                                                                                                                          | 17/03/2016 | 26/05/2016 | SmPC, Annex II, Labelling and PL | Human female fertility may be irreversibly compromised by treatmentwithErivedge.Reversibilityoffertility impairment is unknown.Fertility impairment in human males is not expected. Inthededicated26-weekvismodegibratfertilitystudy,the absoluteweightsoftheseminalvesiclesweresignificantly increased. After recovery, organ weights to the terminal bodyweightwerealsosignificantlyincreasedforthe epididymis,caudaepididymis,testes,seminalvesicles and prostate.No effects on male reproductive organs or on malefertilityendpoints,includingpercentmotilesperm, wereobserved at100mg/kg/dayattheendofdosingor recoveryphase(correspondingto1.3-foldof thesteady- state Auc0-24h at the recommendedhuman dose).In addition,inthevismodegibgeneraltoxicitystudiesupto 26-week in sexually mature rats and dogs, no effects on |

<div style=\"page-break-after: always\"></div>

|                     |                                                                                                                                |            |            |      | malereproductive organswere observed.Increased number of degenerating germ cells and hypospermia in sexuallyimmaturedogsobservedat≥50mg/kg/dayinthe 4-weekgeneral toxicitystudywasof undetermined relationshiptovismodegib. Inthededicated26-weekvismodegibratfertilitystudy, vismodegib-relatedeffectsonfemalereproductiveorgans were observed at 100 mg/kg/day immediately after treatment discontinuation,including decreased implantations,increased percent preimplantation loss,and decreasednumberofdamswithviableembryos.Similar findings were not observed after a 16 week recovery period.Nocorrelativehistopathologicchangeswere observed.Theexposureinfemaleratsat100mg/kg corresponds to1.2-foldof thesteady-stateAUc0-24h at the recommended human dose.In addition,in the vismodegibgeneral26-weektoxicitystudy,decreased number of corpora lutea was observed at 100 mg/kg/day; theeffectwasnotreversedbytheendof an8week recovery period.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10140 /201507 | PeriodicSafetyUpdateEUSingle assessment- vismodegib                                                                            | 11/02/2016 | n/a        |      | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| IB/0022             | B.II.f.1.b.1-Stability of FP -Extension of the shelf lifeof thefinishedproduct-Aspackagedforsale (supported by real time data) | 22/01/2016 | 26/05/2016 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| PSUSA/10140 /201501 | PeriodicSafetyUpdateEUSingle assessment- vismodegib                                                                            | 10/09/2015 | n/a        |      | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |

<div style=\"page-break-after: always\"></div>

| IG/0573   | C.I.8.a-Introductionofor changes to a summary of Pharmacovigilancesystem-ChangesinQPPV (including contact details) and/orchanges in the PSMF location                                                                                                                                                                                                                                                                                                                      | 01/07/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IAIN/0018 | B.I.a.1.a-ChangeinthemanufacturerofASorofa startingmaterial/reagent/intermediateforAS-The proposed manufacturer is part of the same pharmaceuticalgroup asthecurrentlyapproved manufacturer                                                                                                                                                                                                                                                                                | 01/07/2015   | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| R/0016    | Renewalofthemarketingauthorisation.                                                                                                                                                                                                                                                                                                                                                                                                                                        | 26/03/2015   | 27/05/2015 | Annex II    | TheCHMP,havingreviewed the availableinformationon thestatusofthefulfilmentofSpecificObligationsand havingconfirmed thepositivebenefitriskbalance,is ofthe opinionthatthequality,safety andefficacyof this medicinalproductcontinuetobeadequatelyand sufficientlydemonstratedandthereforerecommendsthe renewalof theconditional MAforErivedge,subjecttothe SpecificObligations andConditions aslaiddowninAnnexII to the Opinion. |
| 11/0015/G | This was an applicationfor a group of variations. 1.Following thereviewof theGP28465studyreport, update of SmPC section 4.3 to delete the contraindicationwithStJohn'swort,4.4todelete warningregardingconcomitanttreatmentwith strongCYPinducersand4.5toupdatetheeffectsof concomitantmedicinalproductsonvismodegib.The PL was updated accordingly.In addition, the RMP has beenupdated toreflect thenewlygenerated clinical pharmacologydata.ThisvariationfulfilsMEAO04. | 26/03/2015   | 05/05/2015 | SmPC and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                 |

<div style=\"page-break-after: always\"></div>

| 2.Following thereviewoftheGP27839studyreport as well as new clinical PK and PK modelling data generated since the initial marketing authorization, update of SmPC section 4.2 regarding the posology information for patients with hepatic and renal impairment andsection5.2toreflectthenewPK data generated in patients with hepatic and renal impairment. In addition the RMP has been updated toreflect the newly generated data in patients with hepatic and renal impairment. This variation fulfils MEA 007. 3.Submissionofasummarydocumentoutliningnew non-clinical, clinical PK data generated since the initialmarketing authorization tocomplementthe existingoralcontraceptivedrug-druginteraction data. This variation fulfils MEA 006. The requested group of variations proposed amendmentstotheSummaryofProduct Characteristics andPackageLeaflet and to theRisk Management Plan (RMP). C.I.4 -Change(s) in the SPC, Labelling or PL due to new quality,preclinical, clinical or pharmacovigilance data C.I.4 -Change(s) in the SPC, Labelling or PL due to newquality,preclinical,clinical orpharmacovigilance data C.I.13 - Other variations not specifically covered elsewherein thisAnnexwhichinvolve thesubmission   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| PSUSA/10140 /201407   | PeriodicSafetyUpdateEUSingleassessment-                                                                                                                                                                                                                                                                                                                                                                     | 12/02/2015   | n/a        |                       | PRACRecommendation-maintenance                                                                                                                                                                                                                             |
|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| I1/0008               | Update ofsections4.8 and5.1of theSmPCinorder toupdatethesafetyinformationfromthepooled safetypopulation,afinalSHH4476gpivotal study and aninterim analysis of study M025616.The AnnexIIisbeingupdated todelete therelevant specific obligation. The Package Leaflet is updated accordingly. C.I.4 -Change(s)in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 18/12/2014   | 05/05/2015 | SmPC, Annex II and PL | In this variation the MAH updated frequencies of some side effects including dyspepsia (upset stomach or indigestion) rash, pain (in general) or pain in arms and legs from common to very common based on an analysis of the availablesafety information. |
| IA/0014/G             | Thiswas an applicationfor a groupof variations. B.II.e.7.b - Change in supplier of packaging components or devices (when mentioned in the dossier)-Replacement or additionof asupplier B.II.e.4.a-Change in shape or dimensions of the container or closure (immediate packaging) - Non- sterile medicinal products                                                                                         | 26/11/2014   | n/a        |                       |                                                                                                                                                                                                                                                            |
| IG/0497               | C.I.8.a-Introductionofor changes to a summary of Pharmacovigilance system - Changes in QPPV (includingcontact details)and/or changesin the PSMF location                                                                                                                                                                                                                                                    | 18/11/2014   | n/a        |                       |                                                                                                                                                                                                                                                            |
| IB/0010               | B.I.d.1.a.4-Stability of AS-Change in the re-test                                                                                                                                                                                                                                                                                                                                                           | 15/10/2014   | n/a        |                       |                                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|           | period/storageperiod-Extension orintroductionofa re-testperiod/storageperiodsupportedbyreal time data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |            |     |                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|--------------------------------|
| IB/0011   | B.II.b.1.e-Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch- release, batch control, primary and secondary packaging,fornon-sterilemedicinal products                                                                                                                                                                                                                                                                                                                                                                                   | 08/10/2014 | n/a |                                |
| PSUV/0007 | PeriodicSafetyUpdate                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/09/2014 | n/a | PRACRecommendation-maintenance |
| IA/0009/G | This was an application for a group of variations. B.I.a.4.b-Change to in-process tests or limits appliedduring themanufactureof theAS-Addition ofa newin-processtest andlimits B.II.b.2.a-Change to importer,batch release arrangements andquality controltesting of theFP- Replacement/addition of a site where batch control/testingtakesplace B.II.b.2.a-Change to importer,batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testingtakesplace B.II.e.4.a-Change in shape or dimensions of the container or closure(immediate packaging)-Non- | 04/08/2014 | n/a |                                |

<div style=\"page-break-after: always\"></div>

| R/0006    | Renewalof themarketing authorisation.                                                                                                                                                                                                                                                                                                            | 25/04/2014   | 19/06/2014   |             |                                                                                                                                                                                                                                                                                                    |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 11/0005   | Updateofsection4.5oftheSmPCfurthertothe resultsof aninvitrostudy thatevaluatedwhether vismodegibisasubstrateforor aninhibitor of OATP1B1 and OATP1B3 (MEA 001). The Package Leaflet is updated accordingly. C.I.13-Other variations not specifically covered elsewhereinthisAnnexwhichinvolvethesubmission of studies to the competent authority | 22/05/2014   | 05/05/2015   | SmPC and PL | Invitro,vismodegibis an inhibitor of OATP1B1.It cannot beexcludedthatvismodegibmayincreasetheexposure to substrates of OATP1B1,e.g.bosentan,glibenclamide, repaglinide, valsartan and statins. In particular, caution shouldbeexercisedifvismodegibis administered in combination with any statin. |
| PSUV/0004 | Periodic Safety Update                                                                                                                                                                                                                                                                                                                           | 06/03/2014   | n/a          |             | PRACRecommendation-maintenance                                                                                                                                                                                                                                                                     |
| IA/0002/G | Thiswasanapplicationforagroupofvariations. B.IIl.1.b.3-Submission of a new/updated or deletion of Ph.Eur.TSE Certificate of Suitability· Updatedcertificatefroman alreadyapproved manufacturer B.III.1.b.3-Submission of a new/updated or deletionofPh.Eur.TSECertificateofSuitability Updated certificate from an already approved manufacturer | 11/11/2013   | n/a          |             |                                                                                                                                                                                                                                                                                                    |
| IAIN/0001 | C.I.8.a-Introductionof orchanges to asummary of Pharmacovigilancesystem-ChangesinQPPV (including contact details) and/orchanges in the PSMF location                                                                                                                                                                                             | 18/09/2013   | n/a          |             |                                                                                                                                                                                                                                                                                                    |